Low BL NKCC was associated with advanced disease.

According to COO subtype, 83/485 (17.1%) germinal center B-cell-like (GCB), 37/140 (26.4%) unclassified, and 54/232 (23.3%) activated B-cell-like (ABC) DLBCL patients had low BL NKCC.

Median (range) BL NKCCs were 220 cells/μL (0–3300) in FL and 200 cells/μL (0–1900) in DLBCL patients.

Kaplan–Meier methodology was used to estimate progression-free (PFS) and overall survival (OS), and a Cox regression univariate model was used to estimate corresponding hazard ratio (HR) and confidence interval (CI).

Median score was used to define high/low subgroups.

57-gene signature designed to reflect NK cell tumor infiltration was applied to RNA sequencing data from 552 patients.

Whole transcriptome gene expression in tumor tissue from 552/1418 DLBCL patients.

COO and BL NKCC were available in 857/1418 patients.

Cell-of-origin (COO) was determined in 933/1418 DLBCL patients.

Baseline (BL) peripheral blood (PB) natural killer cell counts (NKCC), assessed by flow cytometry were available in 1064/1202 (88.6%) FL patients and 1287/1418 (90.8%) DLBCL patients.

NK cells are activated and attack the target cell once it’s bound by G/R therefore, it has been suggested that low pre-treatment NK cell count (NKCC) may be associated with worse outcomes in G/R treated patients.

Obinutuzumab (G), an anti-CD20 monoclonal antibody has enhanced direct cell death activity and antibody-dependent cellular cytotoxicity (ADCC) compared to rituximab (R).

“Lymphoma Biology-Non-Genetic Studies: Prognostic Biomarkers and Immune Mechanisms in Lymphoma” this summary is based on data presented at this session and may supersede information in the pre-published ASH Abstract.

The abstract (#727), “Low Peripheral Blood NK Cell Count Is Associated with Worse Clinical Outcome in Patients with Follicular Lymphoma (FL) and Diffuse Large B-Cell Lymphoma (DLBCL) Treated with Immunochemotherapy: Results from the Frontline Phase 3 GALLIUM and GOYA Trials,” was presented during Oral Session 622. He dominated the fight and they had him losing the first four rounds which I thought was stupid.On Monday 11 December 2017 during an oral abstract session at the 59 th Annual meeting American Society of Hematology (ASH), Magdalena Klanova of the Charles University General Hospital in Prague, Czech Republic on behalf of her colleagues, presented results from an exploratory, post-hoc analysis of the phase III GALLIUM and GOYA clinical trials in follicular lymphoma (FL) and diffuse large B-cell lymphoma (DLBCL). 'Any knockdown would have been the excuse to give Canelo the win. 'The strategy we laid out for him was to outbox him and use his jab to go and play Canelo's game,' Diaz commented. The Aztec trainer highlighted that the key to take the victory was the strategy with which they approached the fight and acknowledged that he was afraid that at some point a fall of Bivol could change the judges' decision, but that did not happen.

It was last May 7 in Las Vegas that Dmitry Bivol won on the scorecards against Canelo Alvarez, and the judges' decision was a triple 115-113, so there was no doubt about the Russian's victory over the Mexican. That he already set the goal and that way we gained two weeks of preparation before the official announcement.' Bivol successfully defended his title against Canelo 'I told him to get ready, that I knew well that Canelo already had him on his list and to start training. 'Some time before, Dmitry approached me and told me that he didn't believe the fight was going to happen,' said Diaz in an interview with the YouTube channel ESNEWS.

Nhl 20 strategies